409 related articles for article (PubMed ID: 21162631)
21. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil.
Merker A; Danziger LH; Rodvold KA; Glowacki RC
Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1741-50. PubMed ID: 25347329
[TBL] [Abstract][Full Text] [Related]
22. Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010.
Flamm RK; Sader HS; Jones RN
Braz J Infect Dis; 2013; 17(5):564-72. PubMed ID: 23916453
[TBL] [Abstract][Full Text] [Related]
23. Ceftaroline for complicated skin and skin-structure infections.
Nannini EC; Stryjewski ME; Corey GR
Expert Opin Pharmacother; 2010 May; 11(7):1197-206. PubMed ID: 20402556
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
Drusano GL
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
[TBL] [Abstract][Full Text] [Related]
25. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Farrell DJ; Flamm RK; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
[TBL] [Abstract][Full Text] [Related]
26. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.
Schirmer PL; Deresinski SC
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):777-91. PubMed ID: 19735220
[TBL] [Abstract][Full Text] [Related]
27. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
29. Ceftaroline: a cephalosporin with expanded Gram-positive activity.
Kanafani ZA; Corey GR
Future Microbiol; 2009 Feb; 4(1):25-33. PubMed ID: 19207097
[TBL] [Abstract][Full Text] [Related]
30. Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.
Zhanel GG; Sniezek G; Schweizer F; Zelenitsky S; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2009; 69(7):809-31. PubMed ID: 19441869
[TBL] [Abstract][Full Text] [Related]
31. Ceftaroline fosamil: a novel broad-spectrum cephalosporin.
Bazan JA; Martin SI
Drugs Today (Barc); 2010 Oct; 46(10):743-55. PubMed ID: 21076711
[TBL] [Abstract][Full Text] [Related]
32. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
Barbour A; Schmidt S; Rand KH; Derendorf H
Int J Antimicrob Agents; 2009 Jul; 34(1):1-7. PubMed ID: 19261449
[TBL] [Abstract][Full Text] [Related]
33. Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.
Frampton JE
Drugs; 2013 Jul; 73(10):1067-94. PubMed ID: 23801418
[TBL] [Abstract][Full Text] [Related]
34. [Ceftaroline fosamil, a broad spectrum cephalosporin antibiotic for the treatment of community-acquired pneumonia and complicated skin and skin structure infections].
Nikitin AV
Antibiot Khimioter; 2011; 56(7-8):47-9. PubMed ID: 22359871
[No Abstract] [Full Text] [Related]
35. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
Anderson SD; Gums JG
Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
Canut A; Isla A; Rodríguez-Gascón A
Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
[TBL] [Abstract][Full Text] [Related]
37. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections.
Beresford E; Biek D; Jandourek A; Mawal Y; Riccobene T; Friedland HD
Expert Rev Clin Pharmacol; 2014 Mar; 7(2):123-35. PubMed ID: 24494793
[TBL] [Abstract][Full Text] [Related]
38. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
[TBL] [Abstract][Full Text] [Related]
39. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study.
Jones RN; Mendes RE; Sader HS
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv17-31. PubMed ID: 21115451
[TBL] [Abstract][Full Text] [Related]
40. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
Pfaller MA; Farrell DJ; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
